Phase Ib trial combining capecitabine, erlotinib and bevacizumab in pancreatic adenocarcinoma - REBECA trial

Conclusions The study met the primary objective. RP2D was capecitabine 800  mg/m2 bid continuously, erlotinib 150  mg daily, and bevacizumab 10 mg/kg q 2 weeks. The regimen could be applied safely, but demonstrated limited efficacy.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research